Početna › Tumori mozga › Massachusetts › Boston
Kliničke studije za Tumori mozga u gradu Boston, MA
28 studija za Tumori mozga traži sudionike na lokacijama u gradu Boston i okolici (unutar oko 30 milja). Otvorite studiju da biste vidjeli tko se može priključiti i kako kontaktirati tim studije.
Službeni tekst studije (engleski)
Tražite sudionike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
U tijeku regrutacijaFaza 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
U tijeku regrutacijaFaza 1/2
- Tufts Medical Center, Boston
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
U tijeku regrutacijaFaza 1/2
- Dana-Farber Cancer Institute, Boston
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
U tijeku regrutacijaFaza 2
- Local Institution - 0124, Boston
A Phase 1/1b Study of IAM1363 in HER2 Cancers
U tijeku regrutacijaFaza 1
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
U tijeku regrutacija
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
U tijeku regrutacijaFaza 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
U tijeku regrutacijaFaza 1/2
- Dana-Farber Cancer Institute, Boston
Targeted Pediatric High-Grade Glioma Therapy
U tijeku regrutacijaOpažajna studija
- Dana-Farber Cancer Institute, Boston
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
U tijeku regrutacijaFaza 2
- Massachusetts General Hospital, Boston
Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction
U tijeku regrutacijaFaza 2
- Brigham and Women's Hospital / Dana-Farber Cancer Institute, Boston
Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases
U tijeku regrutacijaFaza 2
- Brigham and Women's Hospital, Boston
B7-H3.CD28Z.CART in CNS Neoplasms
U tijeku regrutacijaFaza 1
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Study of Olutasidenib and Temozolomide in HGG
U tijeku regrutacijaFaza 2
- Susan Chi, Boston
Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy
U tijeku regrutacija
- Massachusetts General Hospital, Boston
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
U tijeku regrutacijaOpažajna studija
- Beth Israel Deaconess Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
Palbociclib and Pembrolizumab In Central Nervous System Metastases
U tijeku regrutacijaFaza 2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
U tijeku regrutacijaFaza 3
- Tufts Medical Center, Boston
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
U tijeku regrutacijaFaza 2
- Dana-Farber Cancer Institute, Boston
NTS-WBRT in Brain Metastases
U tijeku regrutacijaFaza 2
- Massachusetts General Hospital Cancer Center, Boston
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
U tijeku regrutacijaFaza 1/2
- Dana Farber Cancer Institute, Boston
NeuroPathways Intervention for Brain Tumor Patients
U tijeku regrutacija
- Massachusetts General Hospital Cancer Center, Boston
Stereotactic Magnetic Resonance Guided Radiation Therapy
U tijeku regrutacija
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
U tijeku regrutacijaRana faza 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
U tijeku regrutacijaFaza 1/2
- Beth Israel Deaconess Medical Center, Boston
ASCENT Intervention for Brain Tumor Patients
U tijeku regrutacija
- Massachusetts General Hospital Cancer Center, Boston
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
U tijeku regrutacijaOpažajna studija
- Massachusetts General Hospital, Boston
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
U tijeku regrutacijaOpažajna studija
- Massachusetts General Hospital, Boston
Studije za Tumori mozga u drugim gradovima
- Houston, TX35 studija
- New York City, NY25 studija
- Washington, DC20 studija
- Los Angeles, CA16 studija
- Miami, FL15 studija
- Durham, NC14 studija
- St. Louis, MO12 studija
- Cleveland, OH11 studija
- Seattle, WA11 studija
- Rochester, MN11 studija
- Baltimore, MD11 studija
- Columbus, OH11 studija
Ostale studije u gradu Boston
- Rak dojke111 studija
- Nemikrocelularni karcinom pluća90 studija
- Rak (sve vrste)86 studija
- Kolorektalni rak63 studija
- Metastatski karcinom63 studija
- Rak pluća62 studija
- Rak jajnika61 studija
- Rak prostate59 studija
- Depresija52 studija
- Rak endometrija50 studija
- Srčano zatajenje44 studija
- Akutna mijeloična leukemija44 studija
Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.